Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients

HIV Medicine

Volumn 11, Issue 2, 2010, Pages 104-113

  Cicconi, P ^a   Cozzi Lepri, A ^b   Castagna, A ^c   Trecarichi, E M ^d   Antinori, A ^e   Gatti, F ^f   Cassola, G ^g   Sighinolfi, L ^h   Castelli, P ⁱ   d'Arminio Monforte, A ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^f UNIVERSITY OF BRESCIA   (Italy)

^g GALLIERA HOSPITAL   (Italy)

^h UNIVERSITY HOSPITAL OF FERRARA   (Italy)

ⁱ H Macerata   (Italy)

Author keywords

Calendar period; First line highly active antiretroviral therapy; Reasons for discontinuation

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INCIDENCE; ITALY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; UNSPECIFIED SIDE EFFECT;

ADULT; AGE FACTORS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; EPIDEMIOLOGIC METHODS; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; ITALY; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREGNANCY; SEX FACTORS; TIME FACTORS; TREATMENT FAILURE; VIRAL LOAD; YOUNG ADULT;

EID: 73549087858     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2009.00750.x     Document Type: Article

References (20)

1. Deeks SG, Hecht FM, Swanson M. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999, 13:F35-F43.
2. Mocroft A, Phillips AN, Miller V. The use and response to second-line protease inhibitor regimens: results from the EuroSIDA Study. AIDS 2001, 15:201-209.
3. Hammer SM, Saag MS, Schechter M. International AIDS Society-USA panel. JAMA 2006, 296:827-843.
4. Vo TT, Ledergerber B, Keiser O. Durability and outcome of initial antiretroviral treatments received during 2000-2005 by patients in the Swiss HIV Cohort Study. J Infect Dis 2008, 197:1685-1694. for the Swiss HIV Cohort Study.
5. Braithwaite RS, Kozal MJ, Chang CC. Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies. AIDS 2007, 21:1579-1589.
6. Hansel A, Bucher HC, Nuesch R, Battegay M. Reasons for discontinuation of first highly active antiretroviral therapy in a cohort of proteinase inhibitor-naïve HIV-infected patients. J Acquir Immune Defic Syndr 2001, 26:191-193.
7. Mocroft A, Youle M, Moore A. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS 2001, 15:185-194.
8. O'Brien ME, Clark RA, Besch L, Myers L, Kissinger P. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr 2003, 34:407-414.
9. Dorrucci M, Pezzotti P, Grisorio B. Time to discontinuation of the first highly active antiretroviral therapy regimen: a comparison between protease-inhibitor and non-nucleoside reverse transcriptase inhibitor-containing regimens. AIDS 2001, 15:1733-1736.
10. Hart E, Curtis H, Wilkins E, Johnson M. National review of first treatment change after starting highly active antiretroviral therapy in antiretroviral-naïve patients. HIV Med 2007, 8:186-191.
11. Mocroft A, Phillips AN, Soriano V. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses 2005, 21:743-752. for the EuroSIDA Study Group.
12. Van Roon EN, Verzijl JM, Juttmann JR, Lenderinck AW, Blans MJ, Egberts ACG. Incidence of discontinuation of highly active antiretroviral therapy (HAART) and its determinants. J Acquir Immune Defic Syndr 1999, 20:290-294.
13. d'Arminio Monforte A, Cozzi Lepri A, Rezza G. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. AIDS 2000, 14:499-507.
14. Yuan Y, L'Italien G, Mukherjee J, Iloeje UH. Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort. HIV Med 2006, 7:156-162.
15. Nicastri E, Leone S, Angeletti C. Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review. J Antimicrob Chemother 2007, 60:724-732.
16. Robinson LS, Westfall AO, Mugaver MJ. Short term discontinuation of HAART regimens more common in vulnerable patient population. AIDS Res Hum Retroviruses 2008, 24:1347-1355.
17. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis 2000, 30((Suppl 2)):S171-S176.
18. Berg MK, Demas PA, Howard AA, Schoenbaum EE, Gourevitch MN, Arnsten JH. Gender differences in factors associated with adherence to antiretroviral therapy. J Gen Internal Med 2004, 19:1111-1117.
19. Rudy BJ, Murphy DA, Harris DR, Muenz L, Ellen J. Patient-related risks for nonadherence to antiretroviral therapy among HIV-infected youth in the United States: a study of prevalence and interactions. AIDS Patient Care STDS 2009
20. Hinkin CH, Hardy DJ, Mason KI. Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS 2004, 18((Suppl 1)):S19-S25.